Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H6D-MC-LVIR | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured by resistive index (RI) in the prostate transition zone.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 5 milligrams (mg) Tadalafil | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tadalafil | Drug | Administered orally, once daily for 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone | Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Baseline, Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone | Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. |
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Chicago | Illinois | 60611 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24938580 | Derived | Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, Kaminetsky J, Da Pozzo L, Esler A, Cox D. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology. 2014 Aug;84(2):412-9. doi: 10.1016/j.urology.2014.02.063. Epub 2014 Jun 14. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Placebo: tablet administered orally, once daily for 8 weeks. |
| FG001 | Tadalafil | Tadalafil: 5-milligram (mg) tablet administered orally, once daily for 8 weeks. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The Primary Analysis Population was defined as all randomized participants who received at least 1 dose of study medication.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Placebo: tablet administered orally, once daily for 8 weeks. |
| BG001 | Tadalafil | Tadalafil: 5-milligram (mg) tablet administered orally, once daily for 8 weeks. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone | Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to blood flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Randomized participants who received at least 1 dose of study medication, had non-missing data (arterial RI in the prostate transition zone) at baseline, and a post-baseline visit. | Posted | Least Squares Mean | Standard Error | ratio | Baseline, Week 8 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Placebo: tablet administered orally, once daily for 8 weeks. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac arrest | Cardiac disorders | MedDRA 15.0 | Systematic Assessment | This event resulted in death. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
The primary and secondary efficacy analyses of resistive index (RI) and color pixel intensity (CPI) were based on centrally-read data.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | Eli Lilly and Company | 800-545-5979 |
| ID | Term |
|---|---|
| D011470 | Prostatic Hyperplasia |
| ID | Term |
|---|---|
| D011469 | Prostatic Diseases |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068581 | Tadalafil |
| ID | Term |
|---|---|
| D002243 | Carbolines |
| D011725 | Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Administered orally, once daily for 8 weeks |
|
| Baseline, Week 4 |
| Change From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck | Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Baseline, Week 4 and Week 8 |
| Change From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck | CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Baseline, Week 4 and Week 8 |
| United States |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Garden City | New York | 11530 | United States |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | New York | New York | 10016 | United States |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Innsbruck | 6020 | Austria |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Bergamo | 24128 | Italy |
| Protocol Violation |
|
| Withdrawal by Subject |
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Erectile Dysfunction (ED) Etiology | Investigator-reported etiology of a participant's ED at baseline. ED was defined as a consistent change in the quality of an erection adversely affecting the participant's satisfaction with sexual intercourse. ED etiology (psychogenic, organic, mixed, or unknown) was based on the investigator's opinion. Only randomized participants with ED at baseline were summarized (Placebo N=33 and Tadalafil N=29). | Number | participants |
|
| ED Severity | Investigator-reported severity of a participant's ED at baseline. ED was defined as a consistent change in the quality of an erection adversely affecting the participant's satisfaction with sexual intercourse. The severity (mild, moderate, or severe) of ED was based on the investigator's opinion. Only randomized participants with ED at baseline were summarized (Placebo N=33 and Tadalafil N=29). | Number | participants |
|
| ED Duration | Participant-reported ED duration (<1 year or ≥1 year). ED was defined as a consistent change in the quality of an erection adversely affecting the participant's satisfaction with sexual intercourse. Only randomized participants with ED at baseline, who had a baseline ED duration assessment, were summarized (Placebo N=32 and Tadalafil N=29). | Number | participants |
|
| Body Mass Index | Body mass index was an estimate of body fat based on body weight divided by height squared. | Mean | Standard Deviation | kilograms per meter-squared (kg/m^2) |
|
| Sitting Diastolic Blood Pressure | Mean | Standard Deviation | millimeters of mercury (mm Hg) |
|
| Sitting Systolic Blood Pressure | Mean | Standard Deviation | millimeters of mercury (mm Hg) |
|
| Baseline Lower Urinary Tract Symptoms (LUTS) Severity | LUTS was reported as moderate [International Prostate Symptom Score (IPSS) Total Score <20] or severe (IPSS Total Score ≥20). The IPSS Total Score was the sum of Questions 1 through 7 in the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represented a greater severity of symptoms. | Number | participants |
|
| Urinary Peak Flow Rate (Qmax) | Qmax was measured in mL/sec using a standard, calibrated flowmeter. Only randomized participants with a valid uroflowmetry assessment at baseline were summarized (Placebo N=48 and Tadalafil N=45). | Mean | Standard Deviation | milliliters per second (mL/sec) |
|
| Postvoid Residual Volume | Postvoid residual volume of urine measured by ultrasound. | Mean | Standard Deviation | milliliters (mL) |
|
| Prostate Specific Antigen | Mean | Standard Deviation | nanograms per milliliter (ng/mL) |
|
Placebo: tablet administered orally, once daily for 8 weeks.
| OG001 | Tadalafil | Tadalafil: 5-milligram (mg) tablet administered orally, once daily for 8 weeks. |
|
|
|
| Secondary | Change From Baseline to 4-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone | Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Randomized participants who received at least 1 dose of study medication, had non-missing data (arterial RI in the prostate transition zone) at baseline, and a post-baseline visit. | Posted | Least Squares Mean | Standard Error | ratio | Baseline, Week 4 |
|
|
|
|
| Secondary | Change From Baseline to 4 and 8 Weeks in Arterial Resistive Index (RI) in the Prostate Peripheral Zone and Bladder Neck | Arterial RI was a measure of vascular resistance using Doppler ultrasound. RI was the ratio of (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and increased as resistance to flow increased. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Randomized participants who received at least 1 dose of study medication. | Posted | Least Squares Mean | Standard Error | ratio | Baseline, Week 4 and Week 8 |
|
|
|
|
| Secondary | Change From Baseline to 4 and 8 Weeks in Color Pixel Intensity (CPI) in the Prostate Transition Zone, Peripheral Zone, and Bladder Neck | CPI quantified blood flow in a pre-specified region of interest by using color Doppler imaging. CPI was the mean color pixel intensity in the region of interest and scores could range from 0 to 160. An increase in CPI reflected an increase in blood flow. The least squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included fixed effects for treatment, region, visit, and treatment-by-visit interaction, baseline as a covariate, a random effect of participant within treatment, and an unstructured covariance matrix. | Randomized participants who received at least 1 dose of study medication. | Posted | Least Squares Mean | Standard Error | units on a scale | Baseline, Week 4 and Week 8 |
|
|
|
|
| 2 |
| 50 |
| 4 |
| 50 |
| EG001 | Tadalafil | Tadalafil: 5-milligram (mg) tablet administered orally, once daily for 8 weeks. | 0 | 47 | 10 | 47 |
|
| Myocardial infarction | Cardiac disorders | MedDRA 15.0 | Systematic Assessment |
|
| Carotid artery stenosis | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
|
| Ischaemic cerebral infarction | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
|
| Gastric disorder | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
|
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 15.0 | Systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
|
| Subcutaneous abscess | Infections and infestations | MedDRA 15.0 | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
|
| Rib fracture | Injury, poisoning and procedural complications | MedDRA 15.0 | Systematic Assessment |
|
| Hypercholesterolaemia | Metabolism and nutrition disorders | MedDRA 15.0 | Systematic Assessment |
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA 15.0 | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA 15.0 | Systematic Assessment |
|
| Depression | Psychiatric disorders | MedDRA 15.0 | Systematic Assessment |
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 15.0 | Systematic Assessment |
|
| Pollakiuria | Renal and urinary disorders | MedDRA 15.0 | Systematic Assessment |
|
| Renal colic | Renal and urinary disorders | MedDRA 15.0 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 15.0 | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 15.0 | Systematic Assessment |
|
Not provided
| D052801 |
| Male Urogenital Diseases |
| D026121 |
| Indole Alkaloids |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006575 | Heterocyclic Compounds, 3-Ring |
| Week 4 Change, Bladder Neck (n=30, 30) |
|
| Week 8 Change, Bladder Neck (n=32, 26) |
|
| Mixed-Model Repeated Measures |
| 0.066 |
The p-value associated with the LS mean difference of change from baseline to Week 8 in the prostate peripheral zone RI was tested at a significance level of 0.05 with no adjustments for multiplicity. |
| Difference in LS Means |
| 0.02 |
| Standard Error of the Mean |
| 0.009 |
| 95 |
| No |
| Superiority or Other |
| Mixed-Model Repeated Measures | 0.195 | The p-value associated with the LS mean difference of change from baseline to Week 4 in bladder neck RI was tested at a significance level of 0.05 with no adjustments for multiplicity. | Difference in LS Means | 0.02 | Standard Error of the Mean | 0.017 | 95 | No | Superiority or Other |
| Mixed-Model Repeated Measures | 0.625 | The p-value associated with the LS mean difference of change from baseline to Week 8 in bladder neck RI was tested at a significance level of 0.05 with no adjustments for multiplicity. | Difference in LS Means | 0.01 | Standard Error of the Mean | 0.022 | 95 | No | Superiority or Other |
| Week 4 Change, Prostate Peripheral Zone (n=44, 43) |
|
| Week 8 Change, Prostate Peripheral Zone (n=43, 38) |
|
| Week 4 Change, Bladder Neck (n=42, 40) |
|
| Week 8 Change, Bladder Neck (n=38, 36) |
|
| Mixed-Model Repeated Measures |
| 0.860 |
The p-value associated with the LS mean difference of change from baseline to Week 8 in the prostate transition zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity. |
| Difference in LS Means |
| 0.51 |
| Standard Error of the Mean |
| 2.867 |
| 95 |
| No |
| Superiority or Other |
| Mixed-Model Repeated Measures | 0.240 | The p-value associated with the LS mean difference of change from baseline to Week 4 in the prostate peripheral zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity. | Difference in LS Means | 3.47 | Standard Error of the Mean | 2.937 | 95 | No | Superiority or Other |
| Mixed-Model Repeated Measures | 0.839 | The p-value associated with the LS mean difference of change from baseline to Week 8 in the prostate peripheral zone CPI was tested at a significance level of 0.05 with no adjustments for multiplicity. | Difference in LS Means | -0.55 | Standard Error of the Mean | 2.729 | 95 | No | Superiority or Other |
| Mixed-Model Repeated Measures | 0.468 | The p-value associated with the LS mean difference of change from baseline to Week 4 in the bladder neck CPI was tested at a significance level of 0.05 with no adjustments for multiplicity. | Difference in LS Means | -4.20 | Standard Error of the Mean | 5.770 | 95 | No | Superiority or Other |
| Mixed-Model Repeated Measures | 0.131 | The p-value associated with the LS mean difference of change from baseline to Week 8 in the bladder neck CPI was tested at a significance level of 0.05 with no adjustments for multiplicity. | Difference in LS Means | 7.93 | Standard Error of the Mean | 5.199 | 95 | No | Superiority or Other |